PRESS RELEASE 05 May 2025 20:00:00 CEST

### AcouSort announces preliminary outcome of rights issue

AcouSort AB (publ) ("AcouSort" or the "Company") today announces the preliminary outcome of the rights issue of shares, which was announced on 6 March 2025 (the "Rights Issue"). The preliminary outcome is that the Rights Issue has been subscribed to a total of approximately 73 percent, of which approximately 17.5 percent were subscribed with subscription rights, approximately 4.2 percent were subscribed without subscription rights and approximately 51.3 percent were subscribed by underwriters. Through the Rights Issue, AcouSort is, based on the preliminary outcome, expected to receive approximately MSEK 24.9 before issuing costs.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, UNITED KINGDOM, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS WHOLLY OR PARTIALLY SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.

The subscription period in the Rights Issue ended on 5 May 2025, and the preliminary results show that 1,495,780 shares, equivalent to approximately 17.5 percent of the Rights Issue, were subscribed for through the support of subscription rights. In addition, 358,545 shares were subscribed for without the support of subscription rights, equivalent to approximately 4.2 percent of the Rights Issue. Thus, the underwriters are allocated approximately 51.3 percent of the Rights Issue, whereby the Rights Issue is preliminary subscribed to a total of approximately 73 percent. AcouSort will thereby, based on the preliminary outcome, receive approximately MSEK 24.9 before issuing costs.

#### **Final outcome**

The final outcome of the Rights Issue is expected to be announced around 6 May 2025. Those who have subscribed for shares without the support of subscription rights will be allocated shares according to the principles set out in the disclosure document published by the Company on 14 April 2025 prepared in accordance with article 1.4 db Regulation (EU) 2017/1129 of the European Parliament and of Counsil of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, Annex IX (the "Disclosure Document"). The subscribed and allocated shares must be paid in cash according to the instructions on the settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee's procedures.

#### Number of shares and share capital

Through the Rights Issue, the share capital in the Company preliminary increases by SEK 622,976.20, from SEK 1,493,414.00 to SEK 2,116,390.20, and the number of shares preliminary increases by 6,229,762 shares, from 14,934,140 shares to 21,163,902 shares, corresponding to a dilution effect of approximately 29.4 percent.

PRESS RELEASE 05 May 2025 20:00:00 CEST

#### Advisors

Penser by Carnegie, Carnegie Investment Bank AB (publ) is the financial advisor and Fredersen Advokatbyrå AB is the legal advisor to AcouSort in connection with the Rights Issue.

#### For further information, please contact:

Torsten Freltoft, CEO AcouSort AB Telephone: +45 2045 0854 E-mail: torsten.freltoft@acousort.com

#### **About AcouSort AB**

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).

#### Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in AcouSort. No action has been taken or will be taken to authorise an offer to the public in any jurisdiction other than Sweden. The invitation to the persons concerned to subscribe for shares in AcouSort is made only through the Disclosure Document published by the Company on 14 April 2025 on the Company's website, **www.acousort.com**. The Disclosure Document does not constitute a prospectus as defined in the provisions of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has neither been reviewed nor approved by the Swedish Financial Supervisory Authority. The offer in the Disclosure Document is exempt from the obligation to publish a prospectus pursuant to Article 1.4 db of the Prospectus Regulation and, accordingly, the Disclosure Document is prepared in accordance with Annex IX to the Prospectus Regulation.

PRESS RELEASE 05 May 2025 20:00:00 CEST

The publication, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions and persons in the jurisdictions where this press release has been published or distributed should inform themselves about and observe such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer or an invitation to acquire or subscribe for any securities in AcouSort in any jurisdiction, neither from AcouSort nor from anyone else.

This press release is not a prospectus within the meaning of the Prospectus Regulation and, accordingly, does not identify or purport to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in AcouSort. The information contained in this press release is for the sole purpose of describing the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information contained in this press release. Any investment decision should, in order for an investor to fully understand the potential risks and rewards associated with the decision to participate in the Rights Issue, be made solely on the basis of the information contained in the Disclosure Document. Accordingly, an investor is advised to read the entire Disclosure Document.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Belarus, Russia or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable law or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in contravention of this guidance may constitute a breach of applicable securities laws.

In the United Kingdom, this document and other materials relating to the securities referred to herein are only being distributed and directed to, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (as defined in section 86(7) of the Financial Services and Markets Act 2000) who are (i) persons who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) "high net worth entities" as referred to in Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). An investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this announcement and should not act or rely on it.

PRESS RELEASE 05 May 2025 20:00:00 CEST

The Company considers that it is engaged in protection-worthy activities under the Screening of Foreign Direct Investments Act (2023:560) (the "FDI Act"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's activities may fall within the scope of the regulation and that the investment may be notifiable. If an investment is notifiable, it must be notified to the Swedish Inspectorate for Strategic Products (ISP) prior to its implementation. An investment may be notifiable if, after the investment is implemented, the investor, any member of its ownership structure or any person on whose behalf the investor is acting, holds voting rights equal to or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 percent of the total number of votes in the Company. An administrative sanction charge may be imposed on the investor if a notifiable investment is made before the ISP has either (i) decided to leave the notification without action or (ii) approved the investment. Each shareholder should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue for the individual investor.

#### Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forwardlooking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forwardlooking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement, except as required by applicable law or stock exchange regulation.

Information to distributors

PRESS RELEASE 05 May 2025 20:00:00 CEST

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65 /EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in the Company have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment").

Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the Company's shares offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company. Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels.

This information is information that AcouSort is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-05 20:00 CEST.